Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus : a pilot trial 1-2

• Material Type: 博士論文
• Title: Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus : a pilot trial
• Volume: 64 1-2
• Author/Editor: Obata, Fumiaki; Tani, Kenji; Yamaguchi, Harutaka; Tabata, Ryo; Bando, Hiroyasu; Imoto, Issei
• Author Heading: Obata, Fumiaki; Tani, Kenji; Yamaguchi, Harutaka; Tabata, Ryo; Bando, Hiroyasu; Imoto, Issei
• Publication, Distribution, etc.: Faculty of Medicine Tokushima University
• Publication Date: 2017-02
• Publication Date (W3CDTF): 2017-02
• Alternative Title: 2型糖尿病患者に対するエンパグリフロジン10mgの連日投与と隔日投与の有効性と安全性の比較検討:パイロット試験; Comparison of treatment in patients
• Periodical title: The Journal of Medical Investigation
• Degree grantor/type: 徳島大学
• Date Granted: 2017-04-27
• Date Granted (W3CDTF): 2017-04-27
• Dissertation Number: 甲第3093号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第3093号
• Text Language Code: eng
• Subject Heading: sodium-glucose transporter 2 inhibitors; type 2 diabetes mellitus; every other day; empagliflozin; weight reduction
• Target Audience: 一般
• Note (General): The terminal elimination half-life (t1/2) of empagliflozin is 13.1 hours. Accordingly, we hypothesized that the administration of empagliflozin every other day might improve glycemic control in patients with type 2 diabetes mellitus, not being inferior to the therapy every day. We investigated the clinical effects and safety of the addition of empagliflozin every day or every other day to type 2 diabetic patients with a poor control in glycemia. Thirteen Japanese patients diagnosed as type 2 diabetes mellitus recruited to this study. Subjects were divided into two groups ; one was treatment with 10 mg of empagliflozin every day (Group A), the other was 10 mg of empagliflozin every other day (Group B). The comparable study of multiple clinical indexes between the 2 groups was made before and 8, 16, and 24 weeks after the treatment. After the treatment for 24 weeks, the HbA1c level was decreased both in group A (from 7.5%±1.1% to 6.5%±0.8%) and in group B (from 7.6%±0.8% to 7.2%±0.5%). This pilot trial suggested the possibility of 10-mg every other day administration with empagliflozin for Japanese patients with type 2 diabetes mellitus.
• DOI: info:doi/10.2152/jmi.64.50; https://doi.org/info:doi/10.2152/jmi.64.50
• Persistent ID (NDL): info:ndljp/pid/10371160; https://dl.ndl.go.jp/pid/10371160
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2017-07-03T04:10:06+09:00
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://repo.lib.tokushima-u.ac.jp/111081
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2019-09-09 再収集